Natco Continues Para IV Charge With $1.2bn Lynparza, FTF ‘Possible’
Indian Firm Also Teases Prospect Of ‘Another Revlimid’ Pipeline Opportunity
Executive Summary
Indian firm Natco is continuing to build its US pipeline and ex-India geographic presence, the company’s management told investors, in the wake of announcing a major paragraph IV patent challenge opportunity.
You may also be interested in...
AstraZeneca Hits And Misses: Trio Of EU Label Expansions But US Lynparza Review Delayed
The major has won two positive CHMP opinions and one EU approval for meaningful label expansions across its oncology and cardiology franchises, but a delayed US review for prostate cancer drug Lynparza has put a spanner in the works.
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.
Waverley Weighs Its Options With High Costs, Thin Margins
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.